Cargando…
Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases
OBJECTIVES: Tricuspid valve (TV) surgery remains understudied and little data exist describing the surgical indications, outcomes, and prognostic factors for pediatric patients with non-Ebstein 2-ventricle congenital TV lesions. This study aims to describe early and late outcomes of pediatric patien...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510886/ https://www.ncbi.nlm.nih.gov/pubmed/36172453 http://dx.doi.org/10.1016/j.xjon.2022.06.017 |
_version_ | 1784797541191122944 |
---|---|
author | Blitzer, David Bouhout, Ismail Al Haddad, Eliana Lewis, Matthew Farooqi, Kanwal Shah, Amee Zemer-Wassercug, Noa Singh, Harsimran Anderson, Brett Bacha, Emile Kalfa, David |
author_facet | Blitzer, David Bouhout, Ismail Al Haddad, Eliana Lewis, Matthew Farooqi, Kanwal Shah, Amee Zemer-Wassercug, Noa Singh, Harsimran Anderson, Brett Bacha, Emile Kalfa, David |
author_sort | Blitzer, David |
collection | PubMed |
description | OBJECTIVES: Tricuspid valve (TV) surgery remains understudied and little data exist describing the surgical indications, outcomes, and prognostic factors for pediatric patients with non-Ebstein 2-ventricle congenital TV lesions. This study aims to describe early and late outcomes of pediatric patients with non-Ebstein congenital TV lesions undergoing isolated TV procedures at a single institution. METHODS: All patients who underwent TV surgery for non-Ebstein congenital TV disease between 2006 and 2018 were included. Patients who had missing preoperative data, patients with single-ventricle physiology, congenitally corrected transposition of the great arteries, and patients undergoing TV intervention as part of repair of an atrioventricular canal defect were excluded. The primary end point was the occurrence of TV reintervention or TV regurgitation (TR) ≥ moderate. RESULTS: A total of 85 patients were included. The tricuspid lesion was isolated TR in 80 (94.1%), isolated tricuspid stenosis in 3 (3.5%) and mixed disease in 2 (2.4%) patients. Median age at surgery was 33 years (interquartile range, 12-53 years). TV repair and TV replacement were performed in 66 (77.6%) and 19 (22.4%) patients, respectively. One (1.2%) patient underwent TV reoperation during the same admission. There was no in-hospital mortality. Median follow-up was 3.3 years (interquartile range, 0.1-4.7 years). The overall cumulative incidence of TV reintervention or TR deemed moderate or greater at 1, 3, and 5 years was 3% ± 2%, 11% ± 4%, and 20% ± 8%. In multivariable analysis, age younger than 12 years (P = .04) and mitral valve regurgitation deemed moderate or greater (P = .01) were independent risk factors for TV reintervention or recurrent TR deemed to be moderate or greater at last follow-up. CONCLUSIONS: TV surgery in patients with non-Ebstein congenital TV disease can be performed with good outcomes. TV reintervention or TR deemed moderate or greater occurred in 20% of patients on midterm follow-up. Patients younger than age 12 years are at higher risk for recurrent TR or TV reintervention, whereas preoperative MR deemed moderate or greater increases this risk, especially in patients older than age 12 years. There was no difference in outcomes between TV replacement and repair. |
format | Online Article Text |
id | pubmed-9510886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95108862022-09-27 Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases Blitzer, David Bouhout, Ismail Al Haddad, Eliana Lewis, Matthew Farooqi, Kanwal Shah, Amee Zemer-Wassercug, Noa Singh, Harsimran Anderson, Brett Bacha, Emile Kalfa, David JTCVS Open Congenital: Tricuspid Valve OBJECTIVES: Tricuspid valve (TV) surgery remains understudied and little data exist describing the surgical indications, outcomes, and prognostic factors for pediatric patients with non-Ebstein 2-ventricle congenital TV lesions. This study aims to describe early and late outcomes of pediatric patients with non-Ebstein congenital TV lesions undergoing isolated TV procedures at a single institution. METHODS: All patients who underwent TV surgery for non-Ebstein congenital TV disease between 2006 and 2018 were included. Patients who had missing preoperative data, patients with single-ventricle physiology, congenitally corrected transposition of the great arteries, and patients undergoing TV intervention as part of repair of an atrioventricular canal defect were excluded. The primary end point was the occurrence of TV reintervention or TV regurgitation (TR) ≥ moderate. RESULTS: A total of 85 patients were included. The tricuspid lesion was isolated TR in 80 (94.1%), isolated tricuspid stenosis in 3 (3.5%) and mixed disease in 2 (2.4%) patients. Median age at surgery was 33 years (interquartile range, 12-53 years). TV repair and TV replacement were performed in 66 (77.6%) and 19 (22.4%) patients, respectively. One (1.2%) patient underwent TV reoperation during the same admission. There was no in-hospital mortality. Median follow-up was 3.3 years (interquartile range, 0.1-4.7 years). The overall cumulative incidence of TV reintervention or TR deemed moderate or greater at 1, 3, and 5 years was 3% ± 2%, 11% ± 4%, and 20% ± 8%. In multivariable analysis, age younger than 12 years (P = .04) and mitral valve regurgitation deemed moderate or greater (P = .01) were independent risk factors for TV reintervention or recurrent TR deemed to be moderate or greater at last follow-up. CONCLUSIONS: TV surgery in patients with non-Ebstein congenital TV disease can be performed with good outcomes. TV reintervention or TR deemed moderate or greater occurred in 20% of patients on midterm follow-up. Patients younger than age 12 years are at higher risk for recurrent TR or TV reintervention, whereas preoperative MR deemed moderate or greater increases this risk, especially in patients older than age 12 years. There was no difference in outcomes between TV replacement and repair. Elsevier 2022-07-05 /pmc/articles/PMC9510886/ /pubmed/36172453 http://dx.doi.org/10.1016/j.xjon.2022.06.017 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Congenital: Tricuspid Valve Blitzer, David Bouhout, Ismail Al Haddad, Eliana Lewis, Matthew Farooqi, Kanwal Shah, Amee Zemer-Wassercug, Noa Singh, Harsimran Anderson, Brett Bacha, Emile Kalfa, David Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title | Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title_full | Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title_fullStr | Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title_full_unstemmed | Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title_short | Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases |
title_sort | outcomes and risk analysis after tricuspid valve surgery for non-ebstein 2-ventricle congenital tricuspid valve diseases |
topic | Congenital: Tricuspid Valve |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510886/ https://www.ncbi.nlm.nih.gov/pubmed/36172453 http://dx.doi.org/10.1016/j.xjon.2022.06.017 |
work_keys_str_mv | AT blitzerdavid outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT bouhoutismail outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT alhaddadeliana outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT lewismatthew outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT farooqikanwal outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT shahamee outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT zemerwassercugnoa outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT singhharsimran outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT andersonbrett outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT bachaemile outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases AT kalfadavid outcomesandriskanalysisaftertricuspidvalvesurgeryfornonebstein2ventriclecongenitaltricuspidvalvediseases |